FAK/aurora kinase-IN-1, identified by its CAS number 2178117-69-4, is a small molecule inhibitor that targets focal adhesion kinase (FAK) and aurora kinases, which are critical in various cellular processes, including cell division and signaling pathways. This compound is primarily studied for its potential therapeutic applications in cancer treatment, as both FAK and aurora kinases are often overexpressed or hyperactivated in tumors, contributing to tumor growth and metastasis. The characteristics of this substance include its ability to interfere with the phosphorylation processes mediated by these kinases, thereby inhibiting cancer cell proliferation and promoting apoptosis. Additionally, it may exhibit selectivity towards certain cancer types, making it a candidate for targeted therapy. The compound's pharmacokinetic properties, such as solubility, stability, and bioavailability, are also crucial for its efficacy and safety profile in clinical settings. Ongoing research aims to elucidate its mechanism of action and optimize its use in combination therapies for enhanced anticancer effects.

FAK/aurora kinase-IN-1

2178117-69-4: FAK/aurora kinase-IN-1, identified by its CAS number 2178117-69-4, is a small molecule inhibitor that targets focal adhesion kinase (FAK) and aurora kinases, which are critical in various cellular processes, including cell division and signaling pathways. This compound is primarily studied for its potential therapeutic applications in cancer treatment, as both FAK and aurora kinases are often overexpressed or hyperactivated in tumors, contributing to tumor growth and metastasis. The characteristics of this substance include its ability to interfere with the phosphorylation processes mediated by these kinases, thereby inhibiting cancer cell proliferation and promoting apoptosis. Additionally, it may exhibit selectivity towards certain cancer types, making it a candidate for targeted therapy. The compound's pharmacokinetic properties, such as solubility, stability, and bioavailability, are also crucial for its efficacy and safety profile in clinical settings. Ongoing research aims to elucidate its mechanism of action and optimize its use in combination therapies for enhanced anticancer effects.

<p>FAK/aurora kinase-IN-1, a dual inhibitor of FAK and aurora kinase, has IC50 values of 6.61 nM and 0.91 nM respectively, and demonstrates anticancer effects (WO2018019252A1; compound 11) [1].</p>

CAS 2178117-69-4

FAK/aurora kinase-IN-1

FAK/aurora kinase-IN-1

Ref: TM-T86400